上述"调研清单"清晰地勾勒出当前外资在A股市场的关注焦点，即以AI为代表的科技和医药两大赛道。 高盛在近日发布的报告中表示，DeepSeek-R1的发布在2025年引发了中国科技公司的强劲反弹。从基本 面来看，高盛估计，未来十年，通过节约成本、提高生产率和创造新的收入机会，AI的广泛应用有望 推动企业盈利每年增长3%。 2025年以来，近800家外资机构合计调研A股上市公司近万次。其中，Point 72资产管理公司以263次调 研位居榜首；高盛、美银证券等国际大行的调研次数也均超过百次。从调研方向来看，科技和医药是外 资机构最为关注的两大赛道。 年内外资调研A股近万次 数据显示，截至12月26日，今年以来共有798家外资机构现身A股上市公司调研名单，合计调研9308 次。 具体来看，被称为"华尔街最疯狂赚钱机器"的Point 72资产管理公司今年以来调研A股上市公司263次， 排名首位。在2023和2024年，Point 72资产管理公司全年分别调研A股上市公司255次、259次，均为当 年外资调研榜第一位，堪称"A股调研劳模"。此外，高盛、美银证券、花旗环球等机构今年以来的调研 次数均超过100次。 从调研 ...

Core Viewpoint - The stock price of United Imaging Healthcare (688271) increased by 2.34% to 130.32 CNY as of December 26, 2025, with a market capitalization of 107.4 billion CNY, ranking 2nd in the medical device sector and 166th in the A-share market [1] Company Announcements - United Imaging Healthcare plans to hold its first extraordinary general meeting of shareholders in 2025 on December 30, 2025, to discuss the proposed daily related party transactions for the year 2026, with an estimated total amount of 1.057 billion CNY [1] - The agenda includes transactions related to the procurement of raw materials, sales of products, provision of services, and trademark licensing, with detailed amounts and proportions specified [1]

从资金流向上来看，当日医疗器械板块主力资金净流出6.29亿元，游资资金净流入1.66亿元，散户资金净 流入4.63亿元。医疗器械板块个股资金流向见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 688013 | 天臣医疗 | 54.60 | 3.14% | 4.54万 | | 2.47 Z | | 301122 | 采纳股份 | 27.55 | 2.99% | 2.17万 | | 5943.98万 | | 688108 | 赛诺医疗 | 20.89 | 2.25% | 57.20万 | | 11.64亿 | | 688198 | 佰仁医疗 | 111.02 | 1.67% | 4979.11 | | 5448.99万 | | 300298 | 三诺生物 | 17.44 | 1.34% | 8.40万 | | 1.47亿 | | 688617 | 惠泰医疗 | 250.54 | 1.11% | 7575.15 | | 1.88亿 | | 688755 | 汉邦科技 | 39 ...

Core Viewpoint - The financial performance of United Imaging Healthcare (688271) shows significant growth in revenue and net profit for the first three quarters of 2025, indicating strong operational efficiency and market demand for its medical imaging and treatment solutions [2]. Financial Performance - For the first three quarters of 2025, the company reported a main revenue of 8.859 billion yuan, a year-on-year increase of 27.39% [2]. - The net profit attributable to shareholders reached 1.12 billion yuan, up 66.91% year-on-year [2]. - The non-recurring net profit was 1.053 billion yuan, reflecting a substantial increase of 126.94% year-on-year [2]. - In Q3 2025 alone, the company achieved a main revenue of 2.843 billion yuan, a remarkable rise of 75.41% year-on-year [2]. - The net profit for Q3 was 122 million yuan, showing a significant increase of 143.8% year-on-year [2]. - The non-recurring net profit for Q3 was 87.6141 million yuan, up 126.24% year-on-year [2]. - The company's debt ratio stands at 30.08%, with investment income of 606.847 million yuan and financial expenses of -438.233 million yuan [2]. - The gross profit margin is reported at 47.02% [2]. Market Activity - As of December 25, 2025, the stock price closed at 129.62 yuan, reflecting an increase of 2.59% [1]. - The trading volume was 48,400 lots, with a total transaction value of 619 million yuan [1]. - The net outflow of main funds was 12.5157 million yuan, accounting for 2.02% of the total transaction value [1]. - Retail investors showed a net inflow of 22.2543 million yuan, representing 3.59% of the total transaction value [1]. Analyst Ratings - In the last 90 days, 25 institutions provided ratings for the stock, with 18 buy ratings and 7 hold ratings [2]. - The average target price set by institutions over the past 90 days is 17.312 billion yuan [2].

Core Viewpoint - The medical device sector is experiencing a rebound, with significant inflows into the medical device ETF fund, indicating positive market sentiment and potential investment opportunities [1][3]. Group 1: Market Performance - The Shanghai Composite Index recorded a seven-day rise, with the medical device ETF fund (159797) increasing by 1.58% for two consecutive days [1]. - The medical device ETF fund has seen a net inflow for six consecutive days, accumulating over 31 million yuan in the last ten days [1]. - Most component stocks of the medical device ETF fund closed in the green, with notable gains from companies such as SINO Medical (up over 14%) and Xiangyu Medical (up over 6%) [3]. Group 2: Procurement Policy - The National Organization for High-Value Medical Consumables announced a centralized procurement document for drug-coated balloons and urological intervention consumables, with submission deadlines set for January 13, 2026 [3]. - The procurement cycle will last until December 31, 2028, indicating a long-term commitment to cost control in the medical device sector [3]. Group 3: Industry Outlook - The outlook for 2026 suggests a focus on innovation and international markets, with domestic demand expected to recover gradually [6]. - The medical device sector is anticipated to benefit from policy support and the increasing market share of leading companies, despite current pressures on domestic demand [6]. - The strategy for 2026 will emphasize overseas expansion and innovative products, which are expected to sustain profit margins amid price declines in traditional business areas [6]. Group 4: Specific Sector Insights - The medical device sector's growth will increasingly rely on domestic manufacturers' technological advancements and expansion into rural healthcare markets [7]. - The high-value consumables market is expected to see continued policy-driven changes, with a focus on optimizing bidding mechanisms and expanding product categories [7]. - The low-value consumables segment is adapting to global trade changes by accelerating overseas production to regain market share lost due to tariffs [8]. Group 5: Future Trends - The in-vitro diagnostics market is experiencing a shift towards domestic brands, which are gaining market share through competitive pricing and distribution advantages [8]. - The home medical device sector is prioritizing internationalization, with leading companies pursuing acquisitions and product registrations abroad to enhance growth prospects [8].

以下文章来源于清科沙丘投研院 ，作者丁宝玉 清科沙丘投研院 . 沙丘投研院——中国投资界的黄埔军校，致力于培育新一代杰出企投家，塑造创投高端人才。我们不仅 分享体系化理论，积极实战，更构筑起"永不毕业"的创投社群，汇聚校友力量，在深度链接与互动中激 发合作，在持续共创与联投中携手向上，一同斩获更大成就。 不同行业，各有其独树一帜的发展脉络与特点。针对该行业的投资策略，也需要随之予以调整。企业 欲在商业世界的激烈角逐中脱颖而出，就必须具备独特的竞争优势，而投资的目标，则是找到这 些"别具一格"的企业。 在沙丘投研院黄埔15期课堂上， 同创伟业管理合伙人 丁宝玉导师 结合过往二十余年的投资经验成 果，分享道：一项投资的成功与否取决于三个关键因素—— 赛道、赛车、赛手 ，并强调 "制定投资 策略的前提，是学会思考底层逻辑" 。其中蕴藏的识人断事之道，往往也是指导经营与投资的关键心 法。 投资决策正确，结果也往往正确吗？什么才是投资人眼中伟大的生意？长期主义的 " 价值投资 " 究竟 要多长？怎样的创始人更容易获得资本青睐？ …… 为回答这些问题，本文谨整理摘录 @同创伟业管 理合伙人、沙丘投研院导师 丁宝玉 课堂分 ...

Group 1 - The core viewpoint of the articles highlights a significant upward movement in the medical device sector, driven by policy changes and market dynamics, with a particular focus on the launch of the sixth batch of high-value medical consumables procurement [1][2] - The medical device index ETF (159898) saw a 1.29% increase, with substantial purchases of 36 million units during trading, indicating strong investor interest [1] - Key stocks within the sector, such as SINO Medical and Mailland, experienced notable gains, with increases exceeding 14% and 11% respectively, reflecting positive market sentiment [1] Group 2 - The sixth batch of national high-value medical consumables procurement is set to begin on January 13, 2026, introducing new mechanisms to prevent malicious low pricing, including the concept of anchor pricing and a multi-revival mechanism [1] - The National Medical Products Administration has released new regulations to support medical device exports, which will take effect on May 1, 2026, aimed at optimizing the process for obtaining export sales certificates [1] - Northeast Securities predicts that 2026 will be a year of value reconstruction for the Chinese medical device sector, driven by improved cash flow in hospitals and expectations of policy optimization [2]

Core Viewpoint - The medical device sector is experiencing a positive shift, driven by new policies and market dynamics, with significant investment opportunities emerging as institutional holdings remain low [3][4]. Group 1: Market Performance - On December 25, major indices rose collectively, with the medical device index ETF (159898) increasing by 1.47%, attracting over 18 million yuan in net inflows during the session [1]. - Key stocks in the sector saw substantial gains, including Sino Medical up over 14%, and other notable increases from MaiLand and Weisi Medical [1]. Group 2: Policy Developments - A new round of national procurement for high-value medical consumables has been initiated, set to open bidding on January 13, 2026, focusing on drug-coated balloons and urological intervention consumables [2][3]. - The introduction of anchor pricing and a multi-revival mechanism in the sixth batch of procurement aims to balance price reductions and prevent malicious underpricing [3]. Group 3: Industry Outlook - The release of the "Regulations on the Management of Export Sales Certificates for Medical Devices" on December 25 is expected to support medical device exports, with implementation starting on May 1, 2026 [3]. - Northeast Securities predicts 2026 will be a year of value reconstruction for the medical device sector, with external pressures leading to improved cash flow for hospitals and procurement decisions [3]. - The medical device industry encompasses a wide range of products and services, with high barriers to entry in the core manufacturing and R&D segments [3]. Group 4: ETF Characteristics - The medical device index ETF (159898) tracks the CSI All-Share Medical Device Index, focusing on sectors such as medical equipment and consumables, with significant holdings in leading companies like Mindray and United Imaging [4]. - The index has a strong representation from the ChiNext and STAR Market, accounting for over 80% of its market cap, highlighting its growth-oriented characteristics [4].

Core Viewpoint - The stock of United Imaging Healthcare has shown a slight increase of 2.01% on December 25, with a current price of 128.89 yuan per share and a total market capitalization of 106.23 billion yuan, despite a net outflow of funds [1] Financial Performance - For the period from January to September 2025, United Imaging Healthcare achieved a revenue of 8.859 billion yuan, representing a year-on-year growth of 27.39%, and a net profit attributable to shareholders of 1.12 billion yuan, which is a 66.91% increase compared to the previous year [2] Shareholder Information - As of September 30, 2025, the number of shareholders of United Imaging Healthcare increased to 32,400, up by 96.28%, while the average circulating shares per person decreased by 29.23% to 25,444 shares [2] - The company has distributed a total of 641 million yuan in dividends since its A-share listing [3] Institutional Holdings - Among the top ten circulating shareholders as of September 30, 2025, Hong Kong Central Clearing Limited holds 19.0356 million shares, a decrease of 2.9809 million shares from the previous period [3] - E Fund's SSE STAR 50 ETF and Huaxia's SSE STAR 50 Component ETF also saw reductions in their holdings, with decreases of 2.5956 million shares and 9.0862 million shares, respectively [3]

Group 1 - In 2025, Chinese companies are shifting from cross-border operations to deeper localization and accelerating globalization in response to changing overseas policies [2] - The U.S. government has implemented policies such as the cancellation of tax exemptions for cross-border packages under $800 and reciprocal tariffs, while the EU has introduced the New Battery Law [2] - Chinese enterprises are transitioning from "single product exports" to "full-chain system output," with market strategies evolving from a focus on Europe and the U.S. to a dual-driven approach involving emerging and traditional markets [2] Group 2 - The EDGE AWARDS recognizes companies that have achieved significant breakthroughs in overseas markets despite fluctuating international conditions, highlighting their contributions to globalization [3] - ECARX has achieved large-scale production and delivery in global markets, securing over $1 billion in overseas orders and achieving profitability in Q3 [3] - Alibaba Cloud is enhancing its global infrastructure to support Chinese enterprises' overseas development, focusing on AI product internationalization and building a global cloud computing network [4] Group 3 - HLA has expanded its global strategy, opening new stores in Southeast Asia, Central Asia, and the Middle East, with overseas revenue increasing by 27.42% [4] - Kudi Coffee has expanded its international presence to 33 countries, with over 18,000 stores globally, ranking third worldwide in the coffee and tea sector [4] - United Imaging Healthcare has seen overseas revenue grow from $40 million to over $2 billion in seven years, with a compound annual growth rate of 93% [5] Group 4 - Pop Mart has experienced explosive growth in overseas revenue, which increased by 437.5% in the first half of 2025, accounting for 40.3% of total revenue [6] - Century Huatong, a leading gaming company, has achieved over $3.8 billion in global revenue from its game "Whiteout Survival" and is actively exploring AI gaming applications [7] - Tongwei Group has a global market share of approximately 30% in polysilicon, with significant growth in component sales across various regions [8] Group 5 - Yanghe Distillery has established a comprehensive international communication system focusing on high-end, platform-based, and localized strategies, covering 86 countries and regions [9] - Yiling Pharmaceutical has successfully registered 17 innovative traditional Chinese medicines in over 50 countries, promoting a multi-faceted approach to global healthcare [10] - The trend of collaborative globalization is emphasized, with companies providing reliable service networks to support Chinese enterprises in overseas markets [11] Group 6 - Amazon Global Selling has facilitated the entry of numerous Chinese sellers into international markets, signing cooperation agreements with various provincial commerce departments [12] - XTransfer offers cross-border financial and risk control services to over 800,000 enterprises, enhancing global competitiveness for small and medium-sized businesses [13] - Huawei Cloud has expanded its global presence with 34 geographic regions and 101 available zones, supporting local industry upgrades in various countries [14] Group 7 - Stripe provides programmable financial services to millions of businesses, enabling Chinese brands to establish payment channels and innovative revenue models as they expand globally [15]